After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...

Sanofi’s divestment continues a trend among pharma companies to divest their consumer health divisions to focus on prescription drugs, recognising that consumer health products require different ...

French pharmaceutical giant Sanofi has received a warning letter from the U.S. Food and Drug Administration following an ...

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank ...

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines.

DarioHealth has beefed up its sales and marketing channels as well as its range of digital health products thanks to a $30 million strategic alliance with drugmaker Sanofi. Under the terms of the ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services ... backed by its innovation efforts. Sanofi’s new products like novel recombinant factor VIII therapy, Altuviiio ...

The deal also allows Sanofi to use Novavax's Covid shot and flagship vaccine technology, Matrix-M adjuvant, to develop new ...